focus -WSS

focus

author：Wikipedia 2025-09-30 22:05:39 - browse：85

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Boston's new lab space is opening empty

WSS

Stories you might have missed in 2023: health, science, medicine

Why scientists need input from humanists on sensitive research

Why depression after traumatic brain injury is distinct

Boston Scientific acquires urology company Axonics for $3.7 billion

Merck to acquire Harpoon Therapeutics for $680 million

Study suggests new cause of Down syndrome: cells linked to aging

entertainment

focus

focus

BioMarin wins approval for gene therapy to treat hemophilia A

How to save health care price transparency rules

Apple is now the first public company to be valued at $3 trillion

Ebola: Gilead Sciences antiviral shows promise as new treatment

Guidelines to prevent youth baseball injuries need more muscle

Ebola: Gilead Sciences antiviral shows promise as new treatment

Guidelines to prevent youth baseball injuries need more muscle

STAT Virtual Event: JPM Recap, Live!

Hepatitis C has a cure — but many Americans still lack access to it

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

explore

Change Healthcare outage fallout shows need for new oversight

FDA early review: GLP

Steward Health Care Massachusetts hospitals face fiscal disaster

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

focus

hotspot

explore

focus